Mechanisms of diabetic cardiomyopathy: focus on inflammation
Bellemare M, Bourcier L, Iglesies-Grau J, et al.
Diabetes Obes Metab. Pub. online 10 Feb 2025.
Leggi
Blu
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial
Aggarwal R, Bhatt DL, Szarek M, et al.
Lancet Diabetes Endocrinol. Pub. online 13 Feb 2025.
Leggi
Differential associations of somatic and cognitive-affective symptoms of depression with inflammation and insulin resistance: cross-sectional and longitudinal results from the Emotional Distress Sub-Study of the GRADE study
Ehrmann D, Krause-Steinrauf H, Uschner D, et al.
Diabetologia. Pub. online 14 Feb 2025.
Leggi
Real-world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes
O’Donnell HK, Simmons KM, Gitelman SE, et al.
Diabetes Obes Metab. Pub. online 13 Feb 2025.
Leggi
Effect of liberal glucose control on critically ill patients: a systematic review and meta-analysis
Ma J, Wang X, Zhang Y, Ge C, et al. BMC Endocr Disord. 2025;25(1):36. Abstract e full text
Leggi
Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial
Hendershot CS, Bremmer MP, Paladino MB, et al.
JAMA Psychiatry. 2025:e244789.
Leggi
Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis
Lin YM, Wu JY, Lee MC, et al.
Eur Heart J Cardiovasc Pharmacother. 2025:pvae093.
Leggi
Continuous glucose monitor metrics from five studies identify participants at risk for type 1 diabetes development
Calhoun P, Spanbauer C, Steck AK, et al.
Diabetologia. Pub. online 11 Feb 2025.
Leggi
Partnership and marriage and risk of type 2 diabetes: a narrative review
Kowall B, Rathmann W
Diabetologia. Pub. online 7 Feb 2025.
Leggi
Glucose-lowering medications and risk of chronic obstructive pulmonary disease exacerbations in patients with type 2 diabetes
Ray A, Paik JM, Wexler DJ, et al.
JAMA Intern Med. 2025:e247811.
Leggi